Our valued partners
UCT-UMC Mainz
The first studies on RAS-MAPK signaling and how flavaglines affect it were done at Universitätsmedizin Mainz. These early findings helped spark the spin-off. We’re proud to keep working closely together and truly appreciate the strong, ongoing partnership that has made so much progress possible.
Indivumed
We’ve been lucky to have Indivumed as a partner, bringing their strength in data-driven technologies, especially during the early steps of drug development and optimization. Their know-how has made a real difference, and we truly enjoy the teamwork that’s helping us advance more efficiently.
HI-TRON - DKFZ
We deeply appreciate our collaboration with HI-TRON DKFZ, one of Europe’s leading oncology centers. Beyond clinical trials, our partnership is enriched by ongoing scientific exchange at many levels. Working together with such a renowned institution truly drives us to advance cancer research and therapies.
MSKCC
We really value our partnership with MSKCC, where some of our clinical studies take place. Their dedication to top-quality medical care and thorough research is something we deeply respect. Collaborating with such a skilled team makes a big difference in helping us develop better treatments for patients.
Baylor College of Medicine
Another great trusted partner is Baylor College of Medicine, where zotatifin clinical research studies are being carried out. Their commitment to scientific excellence, the highest standards in clinical care, and innovative research approaches significantly enhances the quality and impact of our work. Collaborating with such an outstanding research team plays a key role in advancing our shared goal of developing more effective and patient-centered therapies.
University of California San Francisco
We greatly value our partnership with UCSF, whose excellence in clinical care and cutting-edge research strengthens our shared mission to advance medical therapeutic innovation. Bringing together leading experts across disciplines — from genomics and immunology to specialized patient care — they play a pivotal role in driving scientific discovery and improving patient outcomes.
Pfizer
A strategic collaboration with Pfizer focused on the development of a novel eIF4E-targeting molecule aims to selectively modulate oncogenic mRNA translation and disrupt tumor-driven signaling pathways at their source. By combining cutting-edge discovery capabilities with global clinical development expertise, the partnership is designed to advance a highly differentiated program with the potential to deliver first-in-class therapeutic options in oncology.
